Asunaprevir recipients , achieving protocol-defined response ( HCV-RNA below quantification limit at week 4 and undetectable at week 10 ) , were rerandomized at week 12 to continue asunaprevir-based triple therapy or receive placebo plus PegIFN/RBV for weeks 13-24 .